Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.
Peptide A
Muscle Growth
Short-peptide myostatin inhibitor targeting the GDF-8 / activin RIIB pathway.
Peptide B
Muscle Growth
Long-acting IGF-1 analog with reduced binding-protein affinity for sustained signaling.
Typical vial
1 mg
Typical dose
50-200 mcg
Half-life
Variable / poorly characterized for short-peptide formulations
FDA status
Not FDA approved.
Typical vial
1 mg
Typical dose
20-50 mcg
Half-life
~20-30 hours
FDA status
Not FDA approved. Native recombinant rhIGF-1 (mecasermin/Inc…
GDF-8 95 (Myostatin Inhibitor) effects
IGF-1 LR3 effects
GDF-8 95 (Myostatin Inhibitor) side effects
IGF-1 LR3 side effects
GDF-8 95 (Myostatin Inhibitor) dosing ranges
Research / muscle hypertrophy
50-200 mcg · Daily or twice-weekly (SubQ) · Per research protocol
IGF-1 LR3 dosing ranges
Research / muscle hypertrophy
20-50 mcg · Once daily (SubQ or IM), pre- or post-workout · 30-50 days per cycle
Site-specific injection (research)
20-40 mcg per site · Into trained muscle, post-workout · 30-50 days per cycle
GDF-8 95 (Myostatin Inhibitor): Short-peptide myostatin inhibitor targeting the GDF-8 / activin RIIB pathway. Typical dose 50-200 mcg. IGF-1 LR3: Long-acting IGF-1 analog with reduced binding-protein affinity for sustained signaling. Typical dose 20-50 mcg. Both fall under the Muscle Growth category.
Stacking GDF-8 95 (Myostatin Inhibitor) with IGF-1 LR3 is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.
GDF-8 95 (Myostatin Inhibitor) is typically dosed: Daily or twice-weekly (SubQ) for Research / muscle hypertrophy. IGF-1 LR3 is typically dosed: Once daily (SubQ or IM), pre- or post-workout for Research / muscle hypertrophy; Into trained muscle, post-workout for Site-specific injection (research).
GDF-8 95 (Myostatin Inhibitor): Not FDA approved. IGF-1 LR3: Not FDA approved. Native recombinant rhIGF-1 (mecasermin/Increlex) is FDA approved for severe primary IGF-1 deficiency in children, but IGF-1 LR3 itself is not.
Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.
Get Started Free